Corcept Therapeutics Submits New Drug Application To FDA For Its Proprietary, Selective Cortisol Modulator, Relacorilant, To Treat Patients With Cushing's Syndrome
Corcept Therapeutics Submits New Drug Application To FDA For Its Proprietary, Selective Cortisol Modulator, Relacorilant, To Treat Patients With Cushing's Syndrome
Corcept醫療向FDA提交了新藥申請，以其專有的選擇性皮質醇調節劑Relacorilant治療庫欣綜合症患者。
Corcept Therapeutics Submits New Drug Application To FDA For Its Proprietary, Selective Cortisol Modulator, Relacorilant, To Treat Patients With Cushing's Syndrome
Corcept醫療向FDA提交了新藥申請，以其專有的選擇性皮質醇調節劑Relacorilant治療庫欣綜合症患者。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。